General Administration of Sport of China

MYEG PARTNERS CHINA'S BEITOU IT INNOVATION TO SHOWCASE DIGITAL IDENTITY CREDENTIALS SERVICE ON THE ZETRIX BLOCKCHAIN

Retrieved on: 
Monday, September 18, 2023

PETALING JAYA, Malaysia, Sept. 18, 2023 /PRNewswire/ -- MY E.G. Services Berhad ("MYEG") and China's state-owned Guangxi Beitou IT Innovation Technology Investment Group Co., Ltd. ("Beitou IT Innovation") has entered into a collaboration to leverage on the Zetrix blockchain to offer cross-border credentials verification services, paving the way for the digitalisation of vital documents, including major government-issued identity credentials.

Key Points: 
  • Services Berhad ("MYEG") and China's state-owned Guangxi Beitou IT Innovation Technology Investment Group Co., Ltd. ("Beitou IT Innovation") has entered into a collaboration to leverage on the Zetrix blockchain to offer cross-border credentials verification services, paving the way for the digitalisation of vital documents, including major government-issued identity credentials.
  • Harnessing the power of the blockchain, the partners conducted a public demonstration of an application that enables the issuance of digital driving licences as verifiable credentials, starting with Chinese nationals.
  • Chairman of Beitou IT Innovation Mr. Shuiping Lai said: "The collaboration with MYEG is a key step of our ASEAN business development.
  • The digital cross-border credential verification platform based on the international blockchain infrastructure is a very meaningful attempt for both MYEG and Beitou IT Innovation's professional digital teams.

MYEG PARTNERS CHINA'S BEITOU IT INNOVATION TO SHOWCASE DIGITAL IDENTITY CREDENTIALS SERVICE ON THE ZETRIX BLOCKCHAIN

Retrieved on: 
Monday, September 18, 2023

PETALING JAYA, Malaysia, Sept. 18, 2023 /PRNewswire/ -- MY E.G. Services Berhad ("MYEG") and China's state-owned Guangxi Beitou IT Innovation Technology Investment Group Co., Ltd. ("Beitou IT Innovation") has entered into a collaboration to leverage on the Zetrix blockchain to offer cross-border credentials verification services, paving the way for the digitalisation of vital documents, including major government-issued identity credentials.

Key Points: 
  • Services Berhad ("MYEG") and China's state-owned Guangxi Beitou IT Innovation Technology Investment Group Co., Ltd. ("Beitou IT Innovation") has entered into a collaboration to leverage on the Zetrix blockchain to offer cross-border credentials verification services, paving the way for the digitalisation of vital documents, including major government-issued identity credentials.
  • Harnessing the power of the blockchain, the partners conducted a public demonstration of an application that enables the issuance of digital driving licences as verifiable credentials, starting with Chinese nationals.
  • Chairman of Beitou IT Innovation Mr. Shuiping Lai said: "The collaboration with MYEG is a key step of our ASEAN business development.
  • The digital cross-border credential verification platform based on the international blockchain infrastructure is a very meaningful attempt for both MYEG and Beitou IT Innovation's professional digital teams.

Danforth Advisors Extends Variable Resource Model to Preclinical and Clinical Development; Acquires Elite BioPharma Consulting to Add Clinical Development Operations to Range of Capabilities

Retrieved on: 
Wednesday, September 6, 2023

Founders Jill C. Bossi, Shawna H. Evans, and Connacht M. Peterson will continue to lead the Elite team.

Key Points: 
  • Founders Jill C. Bossi, Shawna H. Evans, and Connacht M. Peterson will continue to lead the Elite team.
  • “Our model has proven effective on the general & administrative side for hundreds of life science companies – many of whom we supported from early stages through IPO or acquisition and beyond.
  • We offer comprehensive consulting services through every stage of product development,” said Shawna Evans, Founder and Co-President of Elite.
  • In December 2021, Danforth announced an investment by Avesi Partners, LLC, to accelerate plans to meet an ever-broadening scope of strategic and operational needs for emerging life science companies.

CGTN: BRICS welcomes new members: What does it mean to the world?

Retrieved on: 
Friday, August 25, 2023

At the press conference, the five BRICS leaders offered their congratulations to these six countries and expressed confidence in the bloc's future development.

Key Points: 
  • At the press conference, the five BRICS leaders offered their congratulations to these six countries and expressed confidence in the bloc's future development.
  • "The BRICS expansion is historic and a new starting point for BRICS cooperation," said President Xi.
  • Xi said he believes that as long as the BRICS countries pull together, a lot can be achieved through BRICS cooperation, and a promising future awaits the member countries.
  • Noting BRICS countries have reached agreement on the guiding principles of the BRICS expansion process, Ramaphosa, who chaired the press conference, told reporters, "We value the interests of other countries in building the partnership of BRICS."

CGTN: BRICS welcomes new members: What does it mean to the world?

Retrieved on: 
Friday, August 25, 2023

At the press conference, the five BRICS leaders offered their congratulations to these six countries and expressed confidence in the bloc's future development.

Key Points: 
  • At the press conference, the five BRICS leaders offered their congratulations to these six countries and expressed confidence in the bloc's future development.
  • "The BRICS expansion is historic and a new starting point for BRICS cooperation," said President Xi.
  • Xi said he believes that as long as the BRICS countries pull together, a lot can be achieved through BRICS cooperation, and a promising future awaits the member countries.
  • Noting BRICS countries have reached agreement on the guiding principles of the BRICS expansion process, Ramaphosa, who chaired the press conference, told reporters, "We value the interests of other countries in building the partnership of BRICS."

Grab Reports Second Quarter 2023 Results

Retrieved on: 
Wednesday, August 23, 2023

Notably, our second quarter 2023 Group MTUs and Deliveries GMV were at all-time highs.

Key Points: 
  • Notably, our second quarter 2023 Group MTUs and Deliveries GMV were at all-time highs.
  • Group Adjusted EBITDA margin was (0.4)% for the quarter, an improvement from (4.6)% in the second quarter of 2022 and (1.3)% in the first quarter of 2023.
  • Cash liquidity4 totaled $5.6 billion at the end of the second quarter, compared to $5.8 billion at the end of the prior quarter.
  • Our net cash liquidity5 was $4.9 billion at the end of the second quarter, compared to $5.0 billion at the end of the prior quarter.

TFF Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, August 15, 2023

“We continue to make solid progress in our Phase 2 trials of TFF VORI and TFF TAC and expect to announce initial data by the end of 2023,” said Dr. Harlan Weisman, Chief Executive Officer of TFF Pharmaceuticals.

Key Points: 
  • “We continue to make solid progress in our Phase 2 trials of TFF VORI and TFF TAC and expect to announce initial data by the end of 2023,” said Dr. Harlan Weisman, Chief Executive Officer of TFF Pharmaceuticals.
  • We’ve also launched our EAP for TFF VORI and partnered with Durbin to implement the program across several countries.
  • For the quarter ended June 30, 2023, compared to quarter ended June 30, 2022
    Cash Position: as of June 30, 2023, TFF Pharmaceuticals reported cash and cash equivalents of $7.7 million.
  • Net Loss: TFF Pharmaceuticals reported a net loss for the second quarter of 2023 of $5.0 million, compared to a net loss of $8.7 million for the comparable period in 2022.

SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, August 14, 2023

JERSEY CITY, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • JERSEY CITY, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the second quarter ended June 30, 2023.
  • On June 21, 2023, SCYNEXIS announced the achievement of a $25 million performance-based development milestone under its exclusive license agreement with GSK for ibrexafungerp.
  • Selling, general & administrative (SG&A) expense for Q2 2023 decreased to $7.5 million from $15.8 million for Q2 2022.
  • Total other income was $5.7 million for Q2 2023, versus total other income of $8.4 million for Q2 2022.

Cenntro Electric Group Announces Second Quarter 2023 Unaudited Financial Results

Retrieved on: 
Monday, August 14, 2023

Cenntro Electric Group Limited (NASDAQ: CENN) (“Cenntro” or “the Company”), a leading electric vehicle technology company with advanced, market-validated electric commercial vehicles (“ECVs”), today announced its financial results for the second quarter ended June 30, 2023.

Key Points: 
  • Cenntro Electric Group Limited (NASDAQ: CENN) (“Cenntro” or “the Company”), a leading electric vehicle technology company with advanced, market-validated electric commercial vehicles (“ECVs”), today announced its financial results for the second quarter ended June 30, 2023.
  • “Our sales momentum in the second quarter continued to ramp up as distribution expanded from the first quarter of 2023.
  • Gross margin was 27% in the second quarter of 2023, compared with 5% in the second quarter of 2022.
  • Total operating expenses were approximately $14.2 million in the second quarter of 2023, compared with $14.9 million in the second quarter of 2022.

vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Friday, August 11, 2023

HIGH POINT, N.C. , Aug. 11, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments.

Key Points: 
  • HIGH POINT, N.C. , Aug. 11, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments.
  • Cash Position: The Company’s cash position as of June 30, 2023, was $12.6 million compared to $12.1 million as of December 31, 2022.
  • Net Loss: Net loss attributable to vTv shareholders for the three months ended June 30, 2023, was $5.6 million or $0.07 per basic share.
  • Net loss attributable to vTv shareholders for the comparable period a year ago was $3.2 million or $0.04 per basic share.